Development of Dried Blood Spot Proficiency Testing Materials for Newborn Screening of Lysosomal Diseases Using Recombinant Enzymes
International Journal of Neonatal Screening · 09.06.2026 · 12 (2) · 40
DOI: 10.3390/ijns12020040 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 09.06.2026. Verfasst von Elya Courtney und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ORISE through the U.S. Department of Energy Oak Ridge Institute for Science and Education.
Abstract (Originalsprache)
Lysosomal diseases (LDs, or Lysosomal Storage Disorders) have become increasingly visible in the newborn screening community, with the addition of mucopolysaccharidosis type II (MPS-II) into the Recommended Uniform Screening Panel in August 2022 and Infantile Krabbe disease in June 2024. As more LDs are expected to be considered for screening adoption, the ability to multiplex conditions and expand proficiency testing (PT) using quality control materials is essential. This study examines the use of recombinant enzymes to produce first-tier PT materials for mucopolysaccharidosis type I, MPS-II, Gaucher, Fabry, Krabbe, Pompe, and Niemann–Pick A/B (acid sphingomyelinase deficiency)—adding four disorders to the CDC’s Newborn Screening Quality Assurance Program (NSQAP) LD PT panel. Through an iterative process that included two prototype phases, two pilot phases, and external testing by up to 31 external laboratories, a new manufacturing process was developed for producing high-performing dried blood spot-based LD PT specimens. Materials were evaluated using several methods commonly employed by newborn screening laboratories, including tandem mass spectrometry with flow injection and liquid chromatography, digital microfluidics, and fluorometric assays. This novel process for producing LD PT materials offers several advantages over previous manufacturing methods that relied on immortalized cell lines from affected patients. Improved scalability, for example, has enabled NSQAP to expand LD PT enrollment internationally. Furthermore, the new process makes it easier to support future expansions of the LD screening panel. The updated specimens and expanded program were launched in January 2025.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
ORCID-Profile: Elya Courtney, Samantha L Isenberg, C Austin Pickens, Rachel Lee, Konstantinos Petritis
Förderung
- ORISE through the U.S. Department of Energy Oak Ridge Institute for Science and Education
Zitieren
APA
Courtney, E., Isenberg, S. L., Lim, T., Pickens, C. A., Lee, R., Cuthbert, C., & Petritis, K. (2026). Development of Dried Blood Spot Proficiency Testing Materials for Newborn Screening of Lysosomal Diseases Using Recombinant Enzymes. International Journal of Neonatal Screening, 12(2), 40. https://doi.org/10.3390/ijns12020040
Vancouver
Courtney E, Isenberg SL, Lim T, Pickens CA, Lee R, Cuthbert C, et al. Development of Dried Blood Spot Proficiency Testing Materials for Newborn Screening of Lysosomal Diseases Using Recombinant Enzymes. International Journal of Neonatal Screening. 2026;12(2):40. doi:10.3390/ijns12020040
BibTeX
@article{Courtney2026,
author = {Courtney, Elya and Isenberg, Samantha L and Lim, Timothy and Pickens, C Austin and Lee, Rachel and Cuthbert, Carla and Petritis, Konstantinos},
title = {Development of Dried Blood Spot Proficiency Testing Materials for Newborn Screening of Lysosomal Diseases Using Recombinant Enzymes},
journal = {International Journal of Neonatal Screening},
year = {2026},
volume = {12},
number = {2},
pages = {40},
doi = {10.3390/ijns12020040}
}
EUVIMED